# Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis

> **NCT06398652** · PHASE3 · COMPLETED · sponsor: **Taizhou Mabtech Pharmaceutical Co.,Ltd** · enrollment: 336 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** CMAB015
- **BIOLOGICAL:** Secukinumab

## Key facts

- **NCT ID:** NCT06398652
- **Lead sponsor:** Taizhou Mabtech Pharmaceutical Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-27
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-03-19
- **Target enrollment:** 336 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06398652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06398652, "Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT06398652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*